Table 1.
Clinical trials studying treatment of patients with obesity and depression
Author (year) | Participants | Objectives | Results | Quality of the study |
---|---|---|---|---|
Kiecolt-Glasser et al. [26] (2015) | N=58 women (38 breast cancer survivors and 20 controls) | To study the impact of daily stressors and major depression over metabolic responses related to obesity in the presence of high-calorie food | Stress and depression alter the metabolic response to rich in fat foods increasing obesity (up to 104 kcal more per meal) | Moderate |
Lin et al. [10] (2014) | N=131 (126 of them included in the analysis) patients admitted into acute hospitalization ward diagnosed with major depression | Changes in the Hamilton and functional scale based on body weight and BMI in those patients treated with 20 mg of fluoxetine for 6 weeks | Patients who did not achieve remission had a higher BMI and greater weight before commencing the treatment | Moderate |
High weight and BMI are correlated with a slower improvement in both symptoms and functionality at the end of treatment | ||||
Toups et al. [24] (2013) | N=662 patients with chronic or recurrent major depression, randomized into 3 treatment groups (28 weeks duration, with open phase and single blind phase) BMI was measured before and after the treatment | To assess if BMI has any influence over the response to antidepressant treatment or in its comorbidities | Depression in obesity was common (46.2%) compared to the 25.5% of the sample with normal weight | Moderate |
There were no significant differences in the response to treatment in the different groups | ||||
The comorbidities did vary depending on the weight | ||||
BMI is associated with the clinical presentation and the prevalence of comorbidities, but not to the response in antidepressant treatment |